SARS-CoV-2 (COVID-19) Spike 26P Antibody [1C3H9] | PM-9583

SARS-CoV-2 (COVID-19) Spike 26P Antibody [1C3H9] | PM-9583 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Virus

Homology: Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (36.4%)

Immunogen: Anti-SARS-CoV-2 Spike 26P antibody (PM-9583) was raised against a peptide corresponding to 11 amino acids near the amino terminus of SARS-CoV-2 Spike protein.
The immunogen is located within the first 50 amino acids of SARS-CoV-2 Spike protein.

Research Area: Infectious Disease, COVID-19

Tested Application: E, WB

Application: WB: 1 μg/mL.
Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 Spike 26P antibody detects all other SARS-CoV-2 variant Spike S1 protein, but not SARS-CoV-2 Gamma variant Spike S1 protein by ELISA. All other applications and species not yet tested.

Specificiy: It detects Spike S1 proteins of SARS-CoV-2 WT and variants except gamma variant.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Anti-SARS-CoV-2 Spike 26P antibody is immunoaffinity chromatography purified IgG.

Clonality: Monoclonal

Clone: 1C3H9

Isotype: IgG2b

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SARS-CoV-2 Spike 26P antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SARS-CoV-2 Spike 26P antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SARS-CoV-2 Spike 156-157EF antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , Surface Glycoprotein, Spike protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: In January of 2021 a new lineage of SARS-CoV-2, known as P.1 and named Gamma variant, was discovered in Japan and later spread in Brazil. It is considered a VOC (variant of concern) . This variant carries 10 mutations in spike protein, including N501Y, E484K and K417T in RBD, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Gamma variant (P.1 lineage) was observed globally, which is 3.5 times more contagious as the original one. The Gamma variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent due to the immune escape E484K mutation.